The base excision repair (BER) pathway is initiated following the removal of a base lesion by a DNA glycosylase. 13 Glycosylase excision of the damaged base proceeds via hydrolytic cleavage of the ...

Nucleotide excision repair (NER) is a major conserved DNA repair pathway, which repairs various types of damage in the genome, such as those induced by ultraviolet light and environmental agents.

The tumor suppressor p53 plays an important role in response to DNA damage, including DNA repair. One DNA repair pathway, nucleotide excision repair (NER), has been well-documented to be regulated by ...

A researcher has made a discovery that alters our understanding of how the body's DNA repair process works and may lead to new chemotherapy treatments for cancer and other disorders. Researchers ...

Maintaining the stability of the genome is essential for all organisms, and it is not surprising that damage to DNA has been proposed as an explanation for multiple chronic diseases. 1–5 Conserving a ...

DNA damage has emerged as a major culprit in cancer and many diseases related to aging. The stability of the genome is supported by an intricate machinery of repair, damage tolerance, and checkpoint ...

Association of changes in T regulatory cells (Treg) during nivolumab treatment with melanoma outcome. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not ...

Damage to your DNA is unavoidable. Every day our cells are bombarded by gene-splitting UV radiation or chemical carcinogens. Regular water inside our bodies can cause DNA damage. DNA damage is as ...

The Summit supercomputer revealed how damaged strands of DNA are surgically repaired by a molecular pathway called nucleotide excision repair, or NER. NER’s protein components can change shape to ...

The genetic connections between DNA repair pathways and human cancer predisposition have fueled interest in the proteins that recognize and repair specific sites of DNA damage. The repair enzymes are ...

Adjuvant chemotherapy in elderly patients: An analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10 No significant financial relationships to disclose. This is an ...